Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Mayadev J, Zamarin D, Deng W, Lankes HA, Pesci G, Kim H, Chino JP, Banbury B, Sherry N, Sharon E, Ghamande SA, Ferguson C, Mell L, Holman L, Mathews C, O'Malley D, Olawaiye A, Hopp E, Leath C, Copeland L, Mannel R, O'Cearbhaill R, Aghajanian C, Schilder RJ. Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
-
Tepper SJ, Diamond ML, Hirman J, Asher D, Fiore D, Cady R. Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures. J Neurol. 2024 Dec 12; 272(1):4.
-
Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Dur?n I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open. 2024 Dec; 9(12):103972.
-
Zeng L, Zhu Y, Cui X, Chi J, Uddin A, Zhou Z, Song X, Dai M, Cristofanilli M, Kalinsky K, Wan Y. Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Adv Sci (Weinh). 2024 Oct; 11(40):e2400757.
-
Vlachou E, Johnson ? BA, Guancial E, Lombardo KA, Hoffman-Censits J. Frontline immune checkpoint inhibitors in patients = 90 years with advanced urothelial cancer: a single center experience. Can J Urol. 2024 Jun; 31(3):11875-11879.
-
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2024 Aug 10; 42(23):2790-2799.
-
Neumann S, Alverson B. Nirsevimab: The Hidden Costs. Hosp Pediatr. 2024 May 09; 14(6).
-
Kanter J, Ataga KI, Bhasin N, Guarino S, Kutlar A, Lanzkron S, Manwani D, McGann P, Stowell SR, Tubman VN, Yermilov I, Campos C, Broder MS. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel. Ann Hematol. 2024 Jun; 103(6):1909-1917.
-
Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 Jun; 22(3):102090.
-
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G?m?s M, Mar N, Loriot Y, Fl?chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 07; 390(10):875-888.